Barry R Davis

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint ALLHAT: setting the record straight
    Barry R Davis
    The University of Texas Health Science Center at Houston School of Public Health, Houston, Texas 77030, USA
    Ann Intern Med 141:39-46. 2004
  2. ncbi request reprint Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment t
    Barry R Davis
    The University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA
    Ann Intern Med 137:313-20. 2002
  3. ncbi request reprint Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses--a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study
    Barry R Davis
    University of Texas School of Public Health, Houston, TX 77030, USA
    Stat Med 23:2413-27. 2004
  4. pmc ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses
    Jackson T Wright
    ALLHAT Clinical Trials Center, University of Texas at Houston Health Science Center School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA
    Arch Intern Med 169:832-42. 2009
  5. pmc Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study
    Amy I Lynch
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama 55294 0022, USA
    Pharmacogenet Genomics 22:355-66. 2012
  6. pmc Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Barry R Davis
    University of Texas Health Science Center School of Public Health, Houston, TX 77030, USA
    Circulation 118:2259-67. 2008
  7. pmc Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Linda B Piller
    University of Texas School of Public Health, Houston, TX 77030, USA
    Circulation 124:1811-8. 2011
  8. ncbi request reprint Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Linda B Piller
    University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 77030, USA
    J Clin Hypertens (Greenwich) 8:649-56; quiz 657-8. 2006
  9. ncbi request reprint Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    Barry R Davis
    The University of Texas School of Public Health, Houston, TX 77030, USA
    Circulation 113:2201-10. 2006
  10. ncbi request reprint Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT
    Efrain Reisin
    aSection of Nephrology and Hypertension, Louisiana State University Health Science Center, New Orleans, Louisiana bDivision of Nephrology Hypertension, Mayo Clinic, Rochester, Minnesota cCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, Texas dDivision of Endocrinology, Kaiser Permanente of Georgia and Emory University School of Medicine, Atlanta, Georgia eThe National Heart, Lung, and Blood Institute, Bethesda, Maryland fCenter for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin gHoward University Hypertension and Lipid Clinic, Howard University Hospital, Washington, District of Columbia hVeterans Affairs Medical Center and Wright State University Veterans Affairs Campus, Dayton, Ohio, USA
    J Hypertens 32:1503-13. 2014

Detail Information

Publications43

  1. ncbi request reprint ALLHAT: setting the record straight
    Barry R Davis
    The University of Texas Health Science Center at Houston School of Public Health, Houston, Texas 77030, USA
    Ann Intern Med 141:39-46. 2004
    ....
  2. ncbi request reprint Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment t
    Barry R Davis
    The University of Texas School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA
    Ann Intern Med 137:313-20. 2002
    ..Sixty-eight percent (6167 of 9061) of the former patients and 59% (9081 of 15 256) of the latter patients were given additional medications to achieve a target blood pressure of less than 140/90 mm Hg...
  3. ncbi request reprint Imputing gene-treatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses--a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study
    Barry R Davis
    University of Texas School of Public Health, Houston, TX 77030, USA
    Stat Med 23:2413-27. 2004
    ....
  4. pmc ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses
    Jackson T Wright
    ALLHAT Clinical Trials Center, University of Texas at Houston Health Science Center School of Public Health, 1200 Herman Pressler Street, Houston, TX 77030, USA
    Arch Intern Med 169:832-42. 2009
    ..Thiazides are superior in preventing HF, and new-onset DM associated with thiazides does not increase CVD outcomes...
  5. pmc Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study
    Amy I Lynch
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama 55294 0022, USA
    Pharmacogenet Genomics 22:355-66. 2012
    ..The goal was to identify subgroups of individuals on the basis of their genetic profile who benefit most from a particular treatment...
  6. pmc Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Barry R Davis
    University of Texas Health Science Center School of Public Health, Houston, TX 77030, USA
    Circulation 118:2259-67. 2008
    ....
  7. pmc Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Linda B Piller
    University of Texas School of Public Health, Houston, TX 77030, USA
    Circulation 124:1811-8. 2011
    ..After the randomized phase of the trial ended in 2002, outcomes were determined from administrative databases...
  8. ncbi request reprint Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Linda B Piller
    University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 77030, USA
    J Clin Hypertens (Greenwich) 8:649-56; quiz 657-8. 2006
    ..One patient died following an angioedema episode. The occurrence of angioedema in the angiotensin-converting enzyme inhibitor arm corresponds with previously reported angioedema-angiotensin-converting enzyme inhibitor associations...
  9. ncbi request reprint Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    Barry R Davis
    The University of Texas School of Public Health, Houston, TX 77030, USA
    Circulation 113:2201-10. 2006
    ..The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) stipulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing HF...
  10. ncbi request reprint Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT
    Efrain Reisin
    aSection of Nephrology and Hypertension, Louisiana State University Health Science Center, New Orleans, Louisiana bDivision of Nephrology Hypertension, Mayo Clinic, Rochester, Minnesota cCoordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston, Texas dDivision of Endocrinology, Kaiser Permanente of Georgia and Emory University School of Medicine, Atlanta, Georgia eThe National Heart, Lung, and Blood Institute, Bethesda, Maryland fCenter for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, Wisconsin gHoward University Hypertension and Lipid Clinic, Howard University Hospital, Washington, District of Columbia hVeterans Affairs Medical Center and Wright State University Veterans Affairs Campus, Dayton, Ohio, USA
    J Hypertens 32:1503-13. 2014
    ..9), and obese (BMI >30)]...
  11. pmc Getting clinical trial results into practice: design, implementation, and process evaluation of the ALLHAT Dissemination Project
    L Kay Bartholomew
    University of Texas Health Science Center Houston, School of Public Health, Houston, TX, USA
    Clin Trials 6:329-43. 2009
    ..Conventional dissemination of clinical trial results has inconsistent impact on physician practices. A more comprehensive plan to influence determinants of prescribing practices is warranted...
  12. doi request reprint Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program
    Alpesh B Patel
    Department of Medicine, UMDNJ Robert Wood Johnson Medical School, One Robert Wood Johnson Pl, PO Box 19, New Brunswick, NJ 08903 0019, USA
    Stroke 39:1084-9. 2008
    ..Incident stroke was significantly decreased by treatment in the Systolic Hypertension in Elderly Program (SHEP) Trial, but the reduction in fatal events was not statistically significant...
  13. ncbi request reprint Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Frans H H Leenen
    University of Ottawa Heart Institute, Ottawa, Ontario, Canada
    Hypertension 48:374-84. 2006
    ..Some, but not all, of these differences may be explained by less effective blood pressure control in the lisinopril arm...
  14. ncbi request reprint Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA
    Joshua I Barzilay
    Kaiser Permanente of Georgia, USA
    Arch Intern Med 166:2191-201. 2006
    ....
  15. ncbi request reprint The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis
    Paula T Einhorn
    National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892 7936, USA
    Am Heart J 153:42-53. 2007
    ..However, questions have been raised regarding the validity of the HF diagnosis...
  16. pmc Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study
    Anke Hilse Maitland-van der Zee
    School of Public Health, University of Texas Health Science Center at Houston, 1200 Hermann Pressler, Houston TX, USA
    Am Heart J 153:54-8. 2007
    ....
  17. ncbi request reprint Antihypertensive medications and risk of diabetes mellitus
    Joshua I Barzilay
    Kaiser Permanente of Georgia and the Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA
    Curr Opin Nephrol Hypertens 16:256-60. 2007
    ..We also examine the impact of the glucose-sparing effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on preventing cardiovascular disease...
  18. doi request reprint Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension
    Amy I Lynch
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
    JAMA 299:296-307. 2008
    ..The NPPA gene codes for the precursor of atrial natriuretic polypeptide, suggesting that NPPA may modulate the efficacy of some antihypertensive drugs...
  19. pmc Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Jackson T Wright
    Department of Medicine, General Clinical Research Center, Cleveland, Ohio, USA
    Arch Intern Med 168:207-17. 2008
    ....
  20. ncbi request reprint Angiotensin-converting-enzyme inhibitors and diuretics for hypertension
    Barry R Davis
    N Engl J Med 349:90-3; author reply 90-3. 2003
  21. pmc Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Paul A Heidenreich
    VA Palo Alto Health Care System, Palo Alto, CA, USA
    J Gen Intern Med 23:509-16. 2008
    ..To evaluate the cost-effectiveness of first-line treatments for hypertension...
  22. ncbi request reprint Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9
    Mahboob Rahman
    Am J Hypertens 19:656-7. 2006
  23. ncbi request reprint Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate
    Mahboob Rahman
    Case Western Reserve University, Cleveland, Ohio, USA
    Ann Intern Med 144:172-80. 2006
    ..Chronic kidney disease is common in older patients with hypertension...
  24. ncbi request reprint Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    William C Cushman
    J Clin Hypertens (Greenwich) 4:393-404. 2002
    ..Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified...
  25. ncbi request reprint Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention
    John Kao
    David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095 1717, USA
    Am J Cardiol 93:1347-50, A5. 2004
    ....
  26. ncbi request reprint Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project
    Marc A Pfeffer
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 105:2341-6. 2002
    ..Therapeutic decisions regarding pharmacological therapy should be based on safety and tolerability as well as efficacy data. Clinical trials designed to assess efficacy are often insufficiently powered to generate reliable safety data...
  27. ncbi request reprint Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial
    Satish Kenchaiah
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 148:356-64. 2004
    ..Hypertension is a well-established risk factor for myocardial infarction (MI), but its prognostic importance in survivors of an acute MI is less clear...
  28. ncbi request reprint Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes
    John B Kostis
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903 0019, USA
    Am J Cardiol 95:29-35. 2005
    ..Subjects who had diabetes associated with chlorthalidone had no significant increase in CV events and had a better prognosis than did those who had preexisting diabetes...
  29. ncbi request reprint Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril
    Jackson T Wright
    General Clinical Research Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
    JAMA 293:1595-608. 2005
    ..Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs)...
  30. ncbi request reprint Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Mahboob Rahman
    Division of Nephrology and Hypertension, Case Western Reserve University, University Hospitals of Cleveland, Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA
    Arch Intern Med 165:936-46. 2005
    ....
  31. ncbi request reprint Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study
    Donna K Arnett
    University of Minnesota, Division of Epidemiology, Minneapolis, USA
    Circulation 111:3374-83. 2005
    ....
  32. ncbi request reprint Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Paul K Whelton
    Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA
    Arch Intern Med 165:1401-9. 2005
    ....
  33. ncbi request reprint Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study
    Joshua I Barzilay
    Division of Endocrinology, Kaiser Permanente of Georgia, Tucker, GA 30084, USA
    J Clin Hypertens (Greenwich) 6:116-25. 2004
    ....
  34. ncbi request reprint Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial
    David R Holmes
    Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Circulation 106:1243-50. 2002
    ..No oral agent has shown a beneficial effect on restenosis or on associated major adverse cardiovascular events. In limited trials, the oral agent tranilast has been shown to decrease the frequency of angiographic restenosis after PCI...
  35. ncbi request reprint Analysis of survival data with missing measurements of a time-dependent binary covariate
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biopharm Stat 13:253-70. 2003
    ..An example from the Systolic Hypertension in the Elderly Program was used. Inference on the effect of systolic blood pressure on survival is strongly affected by the number and timing of systolic blood measurements...
  36. ncbi request reprint Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial
    Verghese Mathew
    Mayo Clinic, Gonda 5 South MS 130, 200 First Street SW, Rochester, Minn 55905, USA
    Circulation 109:476-80. 2004
    ..The aim of this study was to determine the influence of diabetes on 9-month outcomes of patients undergoing PCI in the current era...
  37. doi request reprint Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque
    Patrick W Serruys
    Thoraxcenter, Ba583, Erasmus MC, Rotterdam, Netherlands
    Circulation 118:1172-82. 2008
    ....
  38. pmc Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Mahboob Rahman
    Case Western Reserve University, University Hospitals of Cleveland Case Medical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA
    Am J Kidney Dis 52:412-24. 2008
    ..Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear...
  39. pmc Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertensi
    Anke Hilse Maitland-van der Zee
    Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute of Pharmaceutical Sciences UIPS, Utrecht University, Utrecht, The Netherlands
    Pharmacogenet Genomics 18:651-6. 2008
    ..High homocysteine blood concentrations predispose to coronary artery disease and statins influence homocysteine levels...
  40. pmc Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension
    Jeffrey A Cutler
    National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 117:2691-704; discussion 2705. 2008
  41. ncbi request reprint The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    Mahboob Rahman
    Division of Hypertension, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Arch Intern Med 164:969-76. 2004
    ..The prevalence of reduced glomerular filtration rate (GFR) in older hypertensive patients and the relationship between level of GFR and cardiovascular disease (CVD) and its risk factors are not well known...
  42. ncbi request reprint The Society for Clinical Trials supports United States legislation mandating trials registration. Position paper
    Kay Dickersin
    Department of Community Health, Brown University, Providence, RI 02912, USA
    Clin Trials 1:417-20. 2004
    ..Standardized data and a unique identification number would be available for each registered trial...
  43. doi request reprint Home use of automated external defibrillators for sudden cardiac arrest
    Gust H Bardy
    Seattle Institute for Cardiac Research, Seattle, WA 98103 4819, USA
    N Engl J Med 358:1793-804. 2008
    ..Consequently, home use of an automated external defibrillator (AED) might offer an opportunity to improve survival for patients at risk...